AMCP Market Insights Health Plan Best Practices:
Targeted Therapies to Deliver Improved Patient Outcomes in Oncology
This educational activity is not accredited for continuing pharmacy education credit.
This non-promotional, sponsored webinar will review health plan best practice recommendations for targeted therapies in oncology with an impressive panel of oncology and managed care experts.
As the US Market continues to evolve, so does the complexity of payers and providers navigating best practices that ensure their members have access to high-quality, cost-effective medications. AMCP’s Market Insights Best Practice provides recommendations from our managed care members to help their peers make the best coverage and access decisions.
Oncology is seeing accelerated development of new expression-based therapy classes with the potential to deliver unprecedented improvements in patient outcomes. One class of particular interest are antibody-drug conjugates (ADCs). ADCs are amongst the fastest growing drug classes in oncology, as they combine the best features of monoclonal anti-bodies and small molecule drugs, creating a single moiety that is highly specific and cytotoxic. Managed care and payer professionals play a central role in improving value in and access to cancer care.
In this webinar, a panel of experts discuss health plan best practices related to target therapies in oncology. Following the presentation, join the panelists for a live Q&A session.
Learn About:
At the completion of this activity, participants should be able to:
 |
||||||||||||||||||||||||||||||||||
| Expert Faculty: | ||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, registered nurses, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
